Updates are available Correction dated 2022-08-08
Click to view Correction: https://doi.org/10.1038/s41467-022-32459-x
-
Authors
Bartolacci, Caterina
Andreani, Cristina https://orcid.org/0000-0003-3245-670X
Vale, Gonçalo https://orcid.org/0000-0003-1104-0289
Berto, Stefano https://orcid.org/0000-0001-9028-9458
Melegari, Margherita
Crouch, Anna Colleen
Baluya, Dodge L.
Kemble, George
Hodges, Kurt
Starrett, Jacqueline
Politi, Katerina
Starnes, Sandra L.
Lorenzini, Daniele
Raso, Maria Gabriela https://orcid.org/0000-0003-2105-5556
Solis Soto, Luisa M. https://orcid.org/0000-0002-1253-630X
Behrens, Carmen
Kadara, Humam
Gao, Boning https://orcid.org/0000-0002-1382-395X
Wistuba, Ignacio I.
Minna, John D. https://orcid.org/0000-0002-7776-0767
McDonald, Jeffrey G. https://orcid.org/0000-0003-1570-4142
Scaglioni, Pier Paolo https://orcid.org/0000-0002-6036-5138
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA259845-01A1)
Cancer Prevention and Research Institute of Texas (RP150519, RP140672)
- License Information
-
More Information
Article History
Received: 13 April 2021
Accepted: 6 July 2022
First Online: 26 July 2022
Change Date: 8 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-32459-x
Competing interests
: G.K. is CEO and Chief Scientific Officer at Sagimet Biosciences where TVB-3664 has been developed. The other authors declare no competing interests.
